12:00 AM
 | 
Feb 09, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

BM32: Phase IIb data

Data from 141 evaluable patients with grass pollen allergy in a double-blind, European Phase IIb trial showed that subcutaneous BM32 improved the mean daily combined symptom and medication score, the primary endpoint, by 22% vs. placebo (p=0.085). BM32 also significantly reduced rhinoconjunctivitis symptom score during the peak pollen season in the second treatment year by...

Read the full 255 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >